FDA Fast Tracks Approval of Voxelotor to Treat Underlying Cause of Sickle Cell Disease | CheckRare.com
The U.S. Food and Drug Administration (FDA) has approved Oxbryta (voxelotor) to treat persons, 12 years and older, with sickle cell disease.
The U.S. Food and Drug Administration (FDA) has approved Oxbryta (voxelotor) to treat persons, 12 years and older, with sickle cell disease.
We have noticed an unusual activity from your IP 199.16.157.180 and blocked access to this
Cutaneous T-cell lymphoma (CTCL) belongs to the non-Hodgkin lymphoma class of hematologic T-cell lymphoproliferative disorders.
Robin Kate Kelley, MD, Professor of Clinical Medicine Hematology/IOncology, University of California, San Francisco, describes the need for better treatment plans for patients with biliary…
Kimberly Moran, PhD, MBA, Head of US Rare Diseases at UCB, discuses new treatment options for myasthenia gravis,
For hematologic malignancy (HM) patients admitted to the ICU, survival is 49 percent at seven days and 21 percent at 12 months.
We have noticed an unusual activity from your IP 199.16.157.183 and blocked access to this
Dr. Smith-Whitley, pediatric hematologist at the Children’s Hospital of Philadelphia, discusses the advances in sickle cell disease.
Dr. Varshavsky-Yanovsky discusses the safety of elranatamab in Black or African-American patients with multiple myeloma.
Bill Grambley explains how his company attacks health inequalities by providing personalized pharmaceutical care with an AI based platform.
Lisa Machtigall, MD, highlights the latest clinical research about Cushing’s disease from ENDO 2023 in this 30 min CE program.